BCAX — Bicara Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $790.59m
- $300.88m
Annual cashflow statement for Bicara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -37.8 | -52 | -68 |
| Depreciation | |||
| Non-Cash Items | 0.81 | 16 | 7.32 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 4.95 | -9.62 | -14.1 |
| Change in Prepaid Expenses | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | -32.1 | -45.6 | -74.8 |
| Capital Expenditures | -0.192 | -0.586 | -0.071 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | — | 0.062 |
| Sale of Fixed Assets | |||
| Cash from Investing Activities | -0.192 | -0.586 | -0.009 |
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 31.7 | 272 | 334 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -0.573 | 226 | 259 |